Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00165802
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : May 22, 2013
Sponsor:
Information provided by:
Eisai Inc.

Brief Summary:
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 after bolus IV administration, on Day 1 of a 21-day cycle, to patients with advanced solid tumors that have progressed following effective therapy or for which no effective therapy exists.

Condition or disease Intervention/treatment Phase
Cancer, Malignant Tumors Drug: E7974 Phase 1

Detailed Description:
The MTD for the Day 1 21-Day schedule was defined at the 0.45 mg/m2 dose level. The study was terminated prior to full enrollment of the colorectal cancer (CRC) expansion cohort, due to a lack of demonstrated activity resulting in Principal Investigator (PI) loss interest to continue enrollment. Collection of all outstanding data is ongoing and database lock is estimated to be complete in June 2008.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open Label Study of E7974 Administered on Day 1 of a 21-Day Cycle In Patients With Advanced Solid Tumors
Study Start Date : May 2006
Actual Primary Completion Date : December 2007
Actual Study Completion Date : January 2009

Arm Intervention/treatment
Experimental: 1 Drug: E7974
Maximum Tolerated Dose defined as 0.45 mg/m^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.




Primary Outcome Measures :
  1. Determine the maximum tolerated dose of E7974 in patients with Advanced Solid Tumors. [ Time Frame: Duration of each cycle will be 21 days; patients will attend a follow-up visit 30 days after last study treatment. Follow-up for safety and efficacy will occur 6 months after the last patient is accrued to the study. ]

Secondary Outcome Measures :
  1. Assess E7974 for safety, pharmacokinetics (PK) and pharmacodynamics (PD) which will correlate AUC with clinical toxicity and efficacy. [ Time Frame: Duration of each cycle will be 21 days; patients will attend a follow-up visit 30 days after last study treatment. Follow-up for safety and efficacy will occur 6 months after the last patient is accrued to the study. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: At this time, we are only enrolling patients for the MTD cohort that meet all study entry criteria, plus the CRC criterion (Inclusion Criterion #12).Patients who meet all of the inclusion criteria and none of the exclusion criteria will be eligible for entry into the study. Patients must:

  1. Have a histologically or cytologically confirmed advanced solid tumor that has progressed following effective therapy or for which no effective therapy exists (including surgery or radiation therapy).
  2. Be >= 18 years of age.
  3. Have an Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2.
  4. Have a life expectancy of >= 3 months.
  5. Have adequate renal function as evidenced by serum creatinine <= 1.5 mg/dL or creatinine clearance >= 40 mL/minute.
  6. Have adequate bone marrow function as evidenced by absolute neutrophil count >= 1,500/µL, hemoglobin of >= 9 g/dL (may be transfused), and platelet count (not transfused) >= 100,000/µL.
  7. Have adequate liver function as evidenced by bilirubin <= 1.5 x ULN and alanine transaminase (ALT) and aspartate transaminase (AST) <= 3 times the upper limits of normal (ULN), unless related to liver involvement by tumor, in which case <= 5.0 x ULN.
  8. Give written informed consent.
  9. Be willing and able to comply with the study protocol for the duration of the study.
  10. Be willing to undergo blood draw and urine sampling for PK in Cycle 1.
  11. Can have either measurable or non-measurable disease.
  12. If a CRC patient is being treated at the MTD, they must have <= 4 prior regimens in the metastatic setting.

Exclusion Criteria:The presence of one or more of the following criteria will disqualify a patient from enrollment in the study:

  1. Patients who have received chemotherapy within 3 weeks of E7974 treatment start; (six weeks for nitrosoureas).
  2. Patients who have not recovered from any chemotherapy-related or other therapy-related toxicity to < Grade 1 at study entry (excluding alopecia Grade 2).
  3. Patients who have received radiotherapy <= 3 weeks prior to study enrollment, (prior radiation therapy allowed to <25% of the bone marrow), and who have not recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia). Lesions that have been radiated cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy.
  4. Patients who have had major surgery without full recovery or major surgery within three weeks of E7974 treatment start.
  5. Patients with primary brain tumors or metastasis at study entry must have them controlled for > one month by previous treatment, including radiation therapy and /or corticosteroids.
  6. Women who are pregnant or breastfeeding.
  7. Women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test.
  8. Women of childbearing potential unless (1) surgically sterile or (2) physiologically postmenopausal for > 12 months, or (3) using adequate measures (including barrier methods) of contraception.
  9. Fertile men or their partners who are not willing to use contraception.
  10. Patients who have a history of positive testing for Human Immunodeficiency Virus (HIV) and/or have active hepatitis B or active hepatitis C at study entry.
  11. Patients with severe, uncontrolled intercurrent illness or infection.
  12. Patients with medically uncontrolled cardiovascular illness defined as unstable angina or congestive heart failure (CHF), with > symptomatic Grade II New York Heart Association (NYHA) Classification, or myocardial infarction (MI) within six months prior to study entry.
  13. Patients who have received organ allografts requiring immunosuppressive therapy.
  14. Patients who have received investigational drugs including immunotherapy, gene therapy, hormone therapy, biologic therapy, or chemotherapy within the three-week period prior to E7974 treatment start; patients must have recovered from any previous major therapy related toxicity (Grade 3 or 4) to <= Grade 1 at study entry.
  15. Patients with a current history of peripheral neuropathy > CTC Grade 2 (e.g., diabetic or chemotherapy-induced neuropathy).
  16. Patients with a history of uncontrolled seizures.
  17. Patients with other significant diseases or disorders that, in the investigator's opinion, would exclude them from the study.
  18. Patients with marked screening or baseline prolongation QT/QTc interval (QTc interval > 470 mm) using the Fridericia method as the main method of QTc analysis.
  19. Patients with allergy or hypersensitivity to hemiasterlin based product or analogue.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00165802


Locations
Layout table for location information
United States, Florida
Sylvester Comprehensive Cancer Center - University of Miami
Miami, Florida, United States, 33136
United States, New Jersey
Cancer Institute Of New Jersey
New Brunswick, New Jersey, United States, 08903-2681
Sponsors and Collaborators
Eisai Inc.
Investigators
Layout table for investigator information
Study Director: Jenny Zhang Eisai Inc.
Layout table for additonal information
Responsible Party: Eisai Medical Services, Eisai Medical Research Inc.
ClinicalTrials.gov Identifier: NCT00165802    
Other Study ID Numbers: E7974-A001-103
First Posted: September 14, 2005    Key Record Dates
Last Update Posted: May 22, 2013
Last Verified: August 2009
Keywords provided by Eisai Inc.:
Cancer
malignant tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms